The Science of Hyperbaric Oxygen Therapy

Introduction

Hyperbaric oxygen therapy (HBOT) is the medical administration of 100% oxygen at pressures greater than normal atmospheric pressure. Where standard atmospheric pressure at sea level measures 1 atmosphere absolute (ATA), clinical HBOT operates between 1.5 and 3.0 ATA — creating a biophysical environment that fundamentally alters how oxygen dissolves in blood, diffuses into tissue, and triggers cascading cellular responses.

The science of HBOT sits at the intersection of physics, biochemistry, and molecular biology. It is not simply "breathing more oxygen." Pressure is the indispensable variable: without sufficient pressure, the plasma-dissolving effects of Henry's Law, the downstream stem cell mobilization, and the pulsatile gene signaling that underlies neuroplasticity do not occur. Understanding HBOT requires understanding the gas laws that make it work, the specific molecular pathways it activates, and the clinical protocols designed to exploit those mechanisms safely.

Part I: The Physics of Hyperbaric Oxygen

Henry's Law — Gas Dissolution Under Pressure

The cornerstone of HBOT's physiological action is Henry's Law, which states that the amount of gas dissolved in a liquid is directly proportional to the partial pressure of that gas above the liquid. Double the pressure of oxygen over plasma, and you roughly double the dissolved oxygen content in that plasma.

Under normal conditions at 1 ATA breathing room air (21% oxygen), plasma carries approximately 3 mL of dissolved oxygen per liter of blood. Nearly all oxygen transport is performed by hemoglobin, which is already 97–98% saturated. At 3 ATA breathing 100% oxygen — where the partial pressure of oxygen reaches approximately 2,280 mmHg — plasma-dissolved oxygen rises to approximately 60 mL/L of blood, sufficient to meet the resting metabolic demands of the entire body without hemoglobin involvement at all. This concept, demonstrated experimentally by Dutch surgeon Ite Boerema in his landmark 1960 paper "Life Without Blood," established that HBOT could sustain pigs exsanguinated to near-zero hemoglobin if they breathed 100% oxygen at 3 ATA (StatPearls / NCBI, Hyperbaric Physics).

The clinical consequence is profound: plasma-dissolved oxygen is not limited to the radius of a red blood cell's travel. It diffuses independently through interstitial fluid, reaching hypoxic zones that cannot be penetrated by red cells due to edema, crush injury, thrombosis, or radiation-induced microvascular damage. At 2.4 ATA breathing 100% oxygen, the oxygen diffusion radius from a capillary into tissue expands approximately fourfold compared to normoxic conditions (UHMS HBO Indications 2020).

Boyle's Law — Pressure and Volume

Boyle's Law (PV = k at constant temperature) governs the behavior of gas bubbles in tissue: as pressure increases, volume decreases in inverse proportion. At 2 ATA, a gas bubble occupies half its surface-pressure volume. At 3 ATA, it occupies one-third. This is the mechanistic basis for treating arterial gas embolism (AGE) and decompression sickness (DCS): the hyperbaric environment compresses pathological nitrogen bubbles, reduces their obstruction of blood flow, and drives nitrogen back into solution (NCBI StatPearls, Hyperbaric Physics).

Boyle's Law also has clinical relevance for barotrauma: any air-containing space in the body — the middle ear, paranasal sinuses, a pulmonary bleb, or trapped bowel gas — will change volume during pressurization and depressurization. This is why middle-ear barotrauma is the most common HBOT adverse effect, and why untreated pneumothorax is the only absolute contraindication to the therapy.

Dalton's Law of Partial Pressures

Dalton's Law states that the total pressure of a gas mixture equals the sum of the partial pressures of each constituent gas. When chamber pressure is doubled and the patient breathes 100% oxygen, the partial pressure of oxygen (pO₂) doubles accordingly. This is why monoplace and multiplace chambers achieve dramatically different pO₂ values than oxygen delivered at normal atmospheric pressure.

The math illustrates the clinical magnitude:

At 2 ATA breathing 100% oxygen, the UHMS confirms that oxygen tensions in plasma and tissue fluids increase tenfold (1,000%) compared to breathing room air at 1 ATA, and blood oxygen content (hemoglobin + plasma combined) increases by approximately 125% (UHMS HBO Indications 2020).

Why 10–20x More Dissolved Oxygen Matters

In normal tissue, the pO₂ at the mitochondrial level is approximately 3–10 mmHg — the minimum required to sustain oxidative phosphorylation. In hypoxic or ischemic tissue, this level falls toward zero, halting ATP synthesis. At 2.4 ATA breathing 100% oxygen, tissue pO₂ can exceed 1,500 mmHg in areas that still have patent blood vessels, creating a steep concentration gradient that forces oxygen to diffuse further and faster into oxygen-starved zones.

This plasma-borne oxygen can penetrate tissues where red blood cells physically cannot go — through edematous tissue where capillaries are compressed shut, through fibrotic zones where microvascular density has been reduced by radiation, and into the center of large wounds where diffusion distances from intact capillaries are too great for hemoglobin-dependent delivery alone (PMC, Application and Progress of HBOT, 2025).

Part II: The 14+ Mechanisms of Action

HBOT is not a single-mechanism drug. It is a biophysical intervention that triggers a cascade of overlapping molecular events, most of which derive from the elevation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) inside cells — the same signaling molecules used by growth factors, cytokines, and hormones. Stephen Thom's 2011 comprehensive review in Plastic and Reconstructive Surgery identified the principal mechanisms as stemming from intracellular generation of ROS and RNS under hyperoxic conditions, acting as signaling molecules rather than toxic agents (Thom SR, PMC 2011).

1. Hyperoxygenation — Direct Dissolved Oxygen Delivery

The most immediate effect: plasma carries 10–20x more dissolved oxygen than at normal atmospheric pressure, delivering oxygen independently of hemoglobin to ischemic, compressed, or edematous tissue. This sustains mitochondrial oxidative phosphorylation in cells otherwise dependent on anaerobic glycolysis, directly reversing the energy failure driving many wound healing and ischemic conditions (UHMS Indications 2020).

2. Vasoconstriction — The Paradox of Reduced Flow Yet Better Delivery

HBOT causes approximately 20% vasoconstriction of normal arterioles through a reflex response to hyperoxia. Counterintuitively, this reduces edema (by lowering capillary hydrostatic pressure and limiting fluid extravasation) without compromising oxygen delivery, because the massively elevated dissolved plasma oxygen concentration more than compensates for reduced blood flow volume. The net result is improved oxygen delivery to swollen tissues even while flow velocity decreases. This makes HBOT uniquely effective for crush injuries and compartment syndrome where edema itself is the primary delivery barrier (treatnow.org HBOT Mechanisms).

3. Angiogenesis — New Capillary Formation via VEGF

HBOT stimulates vascular endothelial growth factor (VEGF) upregulation and new capillary formation through two interacting pathways. First, the pulsatile nature of intermittent HBOT sessions creates oscillating oxygen gradients — high during treatment, returning toward baseline between sessions — that activate hypoxia-inducible factor-1α (HIF-1α) and its downstream gene targets. Second, HBOT-generated ROS activate the thioredoxin/thioredoxin reductase pathway, which promotes HIF activity even in normoxic conditions between sessions. VEGF is the most specific growth factor for neovascularization, and HBOT has been shown to increase it in wounds, along with bFGF, angiopoietin-2, TGF-β1, PDGF receptor, hepatocyte growth factor, and SDF-1 (Thom SR, PMC 2011).

Robert Marx, DDS, at the University of Miami quantified this in irradiated bone: 20 sessions of HBOT restored microvascular density to 75–85% of normal in tissue where radiation had obliterated the microcirculation. This became the scientific foundation of his landmark 20/10 and 30/10 protocols for preventing and treating osteoradionecrosis (Marx Protocol Review, r3healing.com).

4. Antimicrobial and Bactericidal Effects

HBOT kills or inhibits microorganisms through two distinct pathways. Direct bactericidal action: obligate anaerobic organisms (Clostridium species, Bacteroides) cannot survive in the high-pO₂ environment that HBOT creates in infected tissue. Enhanced oxidative burst: polymorphonuclear leukocytes (PMNs/neutrophils) require molecular oxygen to generate the superoxide radicals that kill bacteria during phagocytosis. In poorly perfused tissue, the pO₂ is too low for effective oxidative burst. HBOT restores and amplifies PMN killing efficiency by up to tenfold in hypoxic tissue. This is why HBOT is a standard adjunct treatment for gas gangrene (clostridial myonecrosis), necrotizing fasciitis, and refractory osteomyelitis (treatnow.org).

5. Stem Cell Mobilization — 8x Increase in CD34+ Cells

This is among the most scientifically striking mechanisms, described by Stephen Thom, MD/PhD at the University of Pennsylvania in a landmark 2006 study published in the American Journal of Physiology: Heart and Circulatory Physiology. HBOT mobilizes CD34+ stem/progenitor cells (SPCs) from bone marrow into the peripheral circulation via a nitric oxide-dependent mechanism. The hyperoxic environment activates endothelial nitric oxide synthase (eNOS) in bone marrow stromal cells, triggering SPC release.

Key findings: A single 2-hour session at 2.0 ATA doubled circulating CD34+ cells. Over a course of 20 treatments, circulating CD34+ cells increased eightfold, with no corresponding increase in total white cell count (avoiding the thrombogenic risk of pharmacological mobilization agents). Mobilized cells express receptors for VEGF-2 and SDF-1, directing them to sites of injury for vasculogenesis (Thom SR et al., PubMed 2006). A subsequent 2014 PMC study confirmed that 2.5 ATA protocols produced higher mobilization efficiency than 2.0 ATA, and that all mobilized cells exhibited increased concentrations of HIF-1, HIF-2, and thioredoxin-1 (PMC 2014, CD34+/CD45-dim).

6. Neovascularization in Irradiated Tissue (The Marx Contribution)

Radiation causes a progressive obliterative endarteritis and cellular dysfunction leading to "3-H tissue" — hypoxic, hypovascular, and hypocellular tissue. This tissue is incapable of supporting wound healing, dental extractions, or reconstructive surgery without intervention. Marx's research established that HBOT reverses these vascular changes by stimulating angiogenesis, restoring microvascular density toward normal over 18–23 treatments, and allowing the tissue to once again support surgical wounding. His prospective randomized trial showed a reduction in wound dehiscence from 48% to 11%, and infections from 24% to 6%, in irradiated tissue (Marx Protocol Review).

7. Anti-Inflammatory Effects — Cytokine Modulation

HBOT suppresses expression of beta-2 integrins (CD11b/CD18) on neutrophils — the adhesion molecules responsible for neutrophil margination and endothelial transmigration that drive ischemia-reperfusion injury. This effect is mediated by HBOT-generated reactive species causing excessive S-nitrosylation of cytoskeletal β-actin, altering actin distribution without impairing neutrophil viability or killing function (Thom SR, PMC 2011).

Systemically, HBOT reduces pro-inflammatory cytokines: TNF-α, IL-6, IL-1β, NF-κB, and IFN-γ are all decreased following treatment. The proposed mechanism involves HBOT-mediated preservation of IκBα (inhibiting NF-κB release), upregulation of heme oxygenase-1, and heat shock protein 70 (HSP-70) expression, creating an anti-inflammatory state despite the presence of oxidative stress. A 2021 systematic review of human studies confirmed these anti-inflammatory effects across multiple cohorts (PMC 2021, HBOT Anti-inflammatory).

8. Mitochondrial Function and Biogenesis

HBOT restores Complex IV (cytochrome c oxidase) activity in mitochondria where it has been inhibited by nitric oxide or carbon monoxide — as occurs in carbon monoxide poisoning and certain forms of neurological injury. It reestablishes the electrochemical gradient across the inner mitochondrial membrane and restarts oxidative phosphorylation. In the brain at 1.5 ATA, HBOT has been shown to restore mitochondrial function after traumatic brain injury, elevate ATP and NAD+ levels in brain tissue, and reduce neuronal cell loss in the hippocampus (hyperbaricoxygentreatment.uk).

9. Reactive Oxygen Species (ROS) Signaling — Beneficial Hormesis

The paradox at the heart of HBOT science: elevated oxygen generates ROS, yet HBOT is anti-inflammatory and pro-healing. The resolution lies in hormesis — the biological principle that low-to-moderate doses of a stressor trigger adaptive protective responses that exceed the initial damage. HBOT-generated ROS at clinical pressures and durations act as signaling molecules activating redox-sensitive transcription factors (NF-κB in its cytoprotective modes, Nrf2, HIF-1α), antioxidant enzyme upregulation (superoxide dismutase, catalase, glutathione peroxidase), and growth factor synthesis. This is distinct from the continuous high-dose oxygen toxicity that occurs at sustained pressures above 3 ATA or with extended exposure (Thom SR, PMC 2011).

10. Reduced Ischemia-Reperfusion Injury — Leukocyte Adherence Reduction

When blood flow is restored to ischemic tissue, the sudden reintroduction of oxygen paradoxically causes injury through a burst of ROS production and neutrophil adherence to endothelium (the "reperfusion injury"). HBOT, by suppressing beta-2 integrin expression on neutrophils, prevents this adherence and the inflammatory cascade it triggers. This mechanism has been demonstrated in brain, heart, lung, liver, skeletal muscle, and intestine, and is the basis for HBOT's role in crush injuries, compromised flaps, and cardiac reperfusion protocols (Thom SR, PMC 2011).

11. Telomere Length and Senescent Cell Reduction

The most dramatic recent finding in HBOT biology comes from the Sagol Center for Hyperbaric Medicine and Research in Israel. Amir Hadanny MD and Shai Efrati MD published a prospective trial in the journal Aging (November 2020) enrolling 35 healthy adults aged 64 and older in 60 daily HBOT sessions at 2 ATA with three air breaks per session.

Results were striking: telomere length in T helper, T cytotoxic, natural killer, and B cells increased significantly by over 20% following HBOT. B cells showed the most dramatic change — a 37.63% increase post-treatment. Simultaneously, senescent T helper cell percentages decreased by 37.30%, and senescent T cytotoxic cells decreased by 10.96%.

This was the first study to demonstrate reversal of key biological hallmarks of aging — telomere shortening and senescent cell accumulation — through a non-pharmacological intervention in humans. The authors hypothesized that the hyperoxic-hypoxic paradox (each air break creating a relative hypoxic signal in the context of overall hyperoxia) drives repeated signaling through HIF-1α and telomerase activation pathways (Hadanny A, Efrati S et al., PubMed 2020; PMC full text).

12. Neuroplasticity — BDNF and Neurogenesis

HBOT stimulates brain-derived neurotrophic factor (BDNF), promotes neurogenesis, and — through the oscillating oxygen signals of intermittent HBOT — activates neuroplasticity in dormant or "idling" neurons that retain structural integrity but have lost metabolic activity. Efrati's 2013 PLOS ONE study demonstrated that HBOT could activate neuroplasticity in chronic post-stroke patients years after injury onset, correlating clinical improvement with SPECT imaging demonstrating restored metabolic activity in anatomically intact but functionally silent regions (Efrati S et al., PLOS ONE 2013).

13. Collagen Synthesis — Fibroblast Proliferation

Collagen deposition is oxygen-dependent: the hydroxylation of proline and lysine residues in procollagen requires molecular oxygen as a cofactor. In hypoxic wound tissue, collagen synthesis halts, impairing tensile strength. HBOT restores local pO₂ above the enzymatic thresholds, enabling fibroblast proliferation and collagen synthesis to resume. In Marx's irradiated tissue models, this collagen synthesis restoration was directly measurable as the mechanism underlying improved wound closure rates (Thom SR, PMC 2011).

14. HIF-1α Paradoxical Regulation — The Hyperoxic-Hypoxic Paradox

Under continuously elevated oxygen, one would expect HIF-1α (hypoxia-inducible factor) to be suppressed, since its canonical mechanism involves stabilization only when prolyl hydroxylases are oxygen-deprived. However, the pulsatile, intermittent nature of HBOT — high oxygen during treatment, relative normoxia (or hypoxia relative to the treatment level) between sessions — creates an oscillating oxygen signal that paradoxically activates HIF-1α and its downstream gene targets, including VEGF and EPO, even in the hyperoxic phase. Research on the hyperoxic-hypoxic paradox (Hadanny & Efrati, 2020, Biomolecules) elaborated this mechanism: the alternating oxygen cycles resemble hypoxic preconditioning, maintaining HIF-1 in an activated state through epigenetic mechanisms involving histone demethylases (PMC 2020, Hyperoxic-Hypoxic Paradox).

15. Gut Microbiome Modulation — Emerging Research

A 2024 open-label prospective study in Chinese CD patients found that 10 sessions of HBOT significantly elevated gut microbial diversity (Shannon index), reduced Proteobacteria and Escherichia, and increased Bifidobacterium and Clostridium XIVa. Fecal microbiota transplantation from post-HBOT donors into colitis mouse models significantly reduced intestinal inflammation — demonstrating a causal relationship between HBOT-induced microbiome changes and anti-inflammatory outcomes (PMC 2024, HBOT and Gut Microbiota in Crohn's). A 2025 PMC review confirmed that HBOT increases oxygen delivery from intestinal mucosal tissue to the lumen, altering microbial composition directly and indirectly through host immune modulation (PMC 2025, Gut Microbiota and HBOT).

Part III: Treatment Protocols

Pressure and Duration Standards

Clinical HBOT sessions are prescribed by pressure (in ATA), duration, and number. The appropriate parameters depend on the indication:

The most common clinical protocol is 90 minutes at 2.0–2.4 ATA, 5 days per week, for 20–60 sessions depending on the indication. Efrati's cognitive and neurological protocols at the Sagol Center typically employ 60 sessions at 2 ATA with three 5-minute air breaks per 90-minute session (Aviv Clinics, HBOT Chamber).

Air Breaks — Preventing Oxygen Toxicity

At pressures of 2.0 ATA and above, a standard protocol includes 5-minute air breaks every 20–30 minutes of oxygen breathing. These breaks serve dual functions:

1. Safety: Brief interruption of 100% oxygen breathing reduces cumulative pulmonary oxygen toxic dose (Unit Pulmonary Toxic Dose, UPTD), maintaining exposure well below the threshold for pulmonary oxygen toxicity.

2. Therapeutic: The air break creates the relative hypoxic signal that activates the hyperoxic-hypoxic paradox, augmenting HIF-1α and telomerase signaling. Notably, Hadanny and Efrati's 2020 telomere study protocol specifically included three air breaks per session to "utilize the hyperoxic hypoxic paradox."

A 2019 PMC study of 88 participants completing 60 daily sessions at 2 ATA with 5-minute air breaks every 20 minutes found no significant negative effects on pulmonary function, and a modest improvement in peak expiratory flow (PMC 2019, HBOT Pulmonary Effects).

"Hard" vs. "Mild" Hyperbaric — A Critical Distinction

The UHMS defines HBOT as breathing 100% oxygen at a minimum of 1.4 ATA. The FDA and clinical community distinguish between:

• Hard hyperbaric (medical-grade): 2.0–3.0 ATA, rigid steel or acrylic pressure vessels, 100% medical oxygen, physician-prescribed. Required for all 14 FDA-cleared Medicare indications.
• Mild hyperbaric: Under 1.5 ATA (and typically 1.3 ATA), soft-sided fabric chambers, often using an oxygen concentrator mask inside the chamber rather than flooding the chamber with pure oxygen. Consumer-market devices. Not FDA-cleared for medical indications.

The UHMS has explicitly noted that "mild hyperbaric" exposures commonly deliver far less than 95% oxygen due to mask fit and gas mixing, further reducing physiological impact. However, some neurological research (particularly Harch's early TBI protocols) has employed 1.5 ATA with apparent benefit, suggesting that even lower pressures can activate relevant mechanisms for certain conditions.

Part IV: Chamber Types and Engineering

Monoplace Chambers

Single-patient rigid cylinders, typically constructed of clear acrylic or steel with acrylic viewports. The entire chamber is pressurized with 100% medical oxygen, meaning the patient breathes the chamber atmosphere directly. Sizes typically accommodate one adult in a supine position. Monoplace chambers:

• Reach 1.5–3.0 ATA
• Are monitored from outside via intercom and visual observation
• Require cotton hospital garments (no flammable or static-generating materials)
• Are the dominant chamber type in U.S. wound care centers
• Major manufacturers include Sechrist Industries, Perry Baromedical, and Hyperbaric Cleared

Fire risk is the principal safety concern unique to monoplace chambers: the 100% oxygen atmosphere supports rapid combustion. All materials in the chamber must meet stringent fire-resistance standards.

Multiplace Chambers

Walk-in pressure vessels accommodating 2 to 20+ patients simultaneously. The chamber itself is pressurized with compressed air (not oxygen), and each patient breathes 100% oxygen through a fitted mask, oro-nasal hood, or endotracheal tube. Key advantages:

• Medical staff can be physically present inside ("inside attendants"), enabling hands-on critical care
• No fire risk from pure oxygen atmosphere (oxygen is confined to breathing equipment)
• Patients can be ambulatory and sit in chairs
• Emergency equipment (ventilators, infusion pumps) can operate inside at pressure
• Higher throughput for busy treatment centers

Major manufacturers include ETC (Environmental Tectonics Corporation), Perry Baromedical, Reimers Systems, and HAUX Life-Support GmbH.

Walk-in / Clinical Hard Chambers

Large-format hard chambers used in major academic medical centers. Notable facilities include:

• Duke University Center for Hyperbaric Medicine — Southeast's regional referral center, multiplace, critical care-capable, 24-hour availability (Duke Hyperbaric Center)
• Long Beach Memorial Medical Center — One of the largest HBOT programs in the United States
• U.S. Navy Experimental Diving Unit (NEDU) at Naval Support Activity Panama City, Florida — The primary source of Navy diving and hyperbaric operational guidance, with the Ocean Simulation Facility capable of simulating depths to 2,250 feet of seawater (NEDU Wikipedia)
• Israeli Air Force Hyperbaric Institute — A leading center for military and research HBOT, affiliated with the broader Israeli hyperbaric medicine research enterprise

Soft / Portable Chambers

Flexible-shell chambers constructed from reinforced urethane or TPU fabric, pressurized with air to 1.3–1.5 ATA. Patients breathe supplemental oxygen (90–95%) through a mask connected to an oxygen concentrator inside the chamber. Critical safety note: these chambers must never be flooded with pure oxygen — the fabric cannot sustain the fire safety requirements for an oxygen-rich atmosphere.

Major brands include:

• OxyHealth (Vitaeris 320, Solace 210, Fortius 420) — Market leader by volume, with over 18,000 chambers sold globally; used by U.S. Special Forces and the International Olympic Committee (OxyHealth)
• Summit to Sea (Shallow Dive, Grand Dive, Grand Dive Vertical) — Made in the USA, FDA-cleared for safety specifications, 1.3 ATA, notable for the first vertical portable chamber design (Summit to Sea)
• Macy-Pan — Leading Chinese manufacturer, widely distributed

Veterinary Chambers

HBOT has been adapted for veterinary medicine, with chambers engineered for canine and equine patients. Large-animal chambers (particularly for horses with tendon and joint injuries) and small-animal chambers (dogs, cats) are commercially available. The same physiological mechanisms apply.

Historical Note: The Cunningham Steel Ball Hospital

The most extraordinary chapter in HBOT history is the Cunningham Sanitarium in Cleveland, Ohio. Dr. Orval J. Cunningham, chairman of anesthesia at the University of Kansas, had observed during the 1918 influenza pandemic that patients who moved from high-altitude Denver to lower-altitude Kansas City appeared to improve, reasoning that atmospheric pressure must have beneficial effects. After building several successful tube chambers and generating clinical results (particularly with pneumonia patients, for whom increased oxygen delivery may have been genuinely helpful), he attracted the patronage of Henry H. Timken of the Timken Roller Bearing Company.

In 1928, the million-dollar Timken Tank opened on the shores of Lake Erie — a five-story, 64-foot-diameter, 900-ton steel sphere containing 38 rooms, 350 portholes, an elevator, crystal chandeliers, and climate control. It could accommodate 40 patients simultaneously at 60 PSI (approximately 5 ATA), pressurized with air. Cunningham claimed it could cure diabetes, cancer, and syphilis through the antibacterial effects of high-pressure oxygen on anaerobic organisms he theorized caused all disease.

The American Medical Association issued a scathing critique in JAMA, demanding evidence that was never produced. The Great Depression compounded the scientific discrediting. In 1934 Cunningham sold the sphere for $500,000. It changed hands once more, became a general hospital that also failed, and was finally scrapped for war materials in 1942 for $25,000 worth of steel. The site now hosts a school. It remains the largest hyperbaric chamber ever built and a cautionary tale about outrunning the evidence base (Cleveland Historical, Cunningham Sanitarium; One Pager ICU).

Part V: Contraindications and Side Effects

Absolute Contraindication

Untreated pneumothorax is the only absolute contraindication to HBOT. The presence of free air in the pleural space, when subjected to hyperbaric pressure and subsequent decompression, can catastrophically expand — converting a stable pneumothorax into a life-threatening tension pneumothorax on ascent. Patients must receive appropriate treatment (thoracostomy tube insertion) before any HBOT exposure. Intraocular gas is sometimes listed as a near-absolute contraindication for any non-life-saving indication (NCBI StatPearls, HBOT Contraindications).

Relative Contraindications

The following require individualized risk-benefit assessment by a hyperbaric physician:

Drug interactions:

• Bleomycin: Previously considered absolute due to association with pulmonary fibrosis and interstitial pneumonitis. Recent evidence indicates many patients can safely receive HBOT if bleomycin exposure was more than 6 months prior, with full pre-treatment pulmonary evaluation (spirometry, blood gases, chest radiograph)
• Doxorubicin: Risk of cardiotoxicity with concurrent use; can be managed by discontinuing doxorubicin at least 24 hours before HBOT
• Cisplatin: Impairs wound healing and fibroblast function; reduces HBOT efficacy for wound/radiation indications; no increased adverse effect risk
• Disulfiram (Antabuse): Inhibits superoxide dismutase, the primary antioxidant defense against oxygen toxicity. Substantially increases seizure risk; must be discontinued with adequate clearance time

Pulmonary conditions:

• COPD with air trapping or bullae: Risk of pneumothorax; risk of loss of hypoxic drive with hyperoxia
• Asthma (uncontrolled): Air trapping and pulmonary barotrauma risk
• History of spontaneous pneumothorax: Increased bleb risk

Other conditions:

• Claustrophobia: Severity-dependent; manageable with anxiolytics in monoplace or multiplace setting
• Congenital spherocytosis: Theoretical hemolysis risk from oxidative stress on fragile RBCs
• Eustachian tube dysfunction / history of ear surgery: Barotrauma risk; may require tympanostomy tubes
• Uncontrolled high fever (>39°C): Lowers seizure threshold
• Epilepsy / seizure history: Uncertain increased risk; manageable with antiepileptics and careful protocol
• Heart failure with reduced ejection fraction: HBOT causes vasoconstriction and increased afterload; manageable with diuresis and fluid restriction
• Pregnancy: Traditionally relative contraindication; HBOT may be justified for life-threatening indications such as CO poisoning

Side Effects

Ear barotrauma is the most common adverse effect, occurring in roughly 2% of treatments. It results from failure to equalize middle ear pressure during pressurization (descent). Prevention: Valsalva training, decongestant nasal sprays, slow compression rates, and tympanostomy tubes for high-risk patients.

Oxygen toxicity presents in two forms:

• CNS oxygen toxicity (Paul Bert Effect): Named for French physiologist Paul Bert, who in 1878 demonstrated convulsions in animals exposed to very high pO₂. At clinical HBOT pressures (2.0–2.4 ATA), CNS toxicity is exceptionally rare — approximately 0.7 per 10,000 treatments at 2.4 ATA (Medscape HBOT). Prodromal symptoms include facial pallor, lip twitching, tinnitus, tunnel vision, vertigo, and nausea. If recognized and oxygen removed, seizures do not progress and cause no lasting harm. At 2.0 ATA, the incidence approaches zero.
• Pulmonary oxygen toxicity (Lorrain-Smith Effect): Named for J. Lorrain Smith, who in 1899 described fatal pneumonia in rats after prolonged exposure to elevated pO₂. In clinical HBOT using standard protocols with air breaks, pulmonary toxicity is clinically insignificant. Symptoms (dry cough, substernal burning) would require many hours of continuous high-pO₂ exposure without air breaks — far exceeding clinical protocols.

Transient myopia occurs in patients undergoing multiple daily sessions and resolves within 6 weeks of treatment completion. It results from lens changes under prolonged hyperoxic stress. Nuclear cataracts have been reported after extremely prolonged therapy (>150–200 total treatment hours) — a threshold rarely approached in standard protocols.

Confinement anxiety is significant in monoplace chambers and manageable with anxiolytics, patient education, and multiplace settings.

Fire and explosion: In monoplace chambers pressurized with 100% oxygen, strict protocols prohibit all static-generating materials, synthetic fabrics, flammable items, and electronic devices. No documented patient deaths from HBOT chamber fires have occurred in properly certified clinical facilities using standard safety protocols.

Part VI: Current Research Frontiers

Telomere Lengthening and the Anti-Aging Protocol

The 2020 Hadanny/Efrati study in Aging (Albany NY) established HBOT as the first intervention to demonstrate reversal of telomere shortening in aging humans. The protocol — 60 sessions of 2 ATA, 90 minutes, with 3 air breaks per session — produced >20% telomere lengthening across immune cell populations, with B cells showing 37.6% gains, and 10–37% reductions in senescent cells (PubMed). This work is the foundation of the Aviv Clinics anti-aging HBOT protocol and has generated intense scientific interest in HBOT as a senolytic intervention.

Stroke Recovery Beyond the Treatment Window

Efrati's 2013 PLOS ONE randomized controlled trial enrolled 74 patients with chronic post-stroke neurological deficits (at least 6 months post-stroke, mean 3.5 years) and demonstrated that 40 sessions at 2 ATA induced significant neurological improvement — NIHSS scores, Activities of Daily Living, and quality of life — with SPECT imaging confirming restored metabolic activity in anatomically intact but previously dormant brain regions. No improvement was observed during the no-treatment control period of the crossover group. The implication: neuroplasticity can be activated years after the acute event in the "idling neuron" population around the infarct (PLOS ONE 2013).

Alzheimer's Disease and Cognitive Aging

Preliminary work from the Sagol Center (Shapira et al., 2021) has examined HBOT's effect on Alzheimer's pathology and age-related cognitive decline, building on the telomere and neuroplasticity findings. The hypothesis is that HBOT-induced angiogenesis and neuroplasticity can slow or reverse early cortical hypoperfusion patterns. Larger controlled trials are ongoing.

Long COVID — Growing Evidence Base

Post-acute sequelae of SARS-CoV-2 (PASC/Long COVID) involves endothelial dysfunction, microthrombi, neuroinflammation, and mitochondrial dysfunction — mechanisms that map directly onto HBOT's known mechanisms. As of 2025, 21 studies have been published, including multiple randomized controlled trials.

Zilberman-Itskovich et al. (2022) — A prospective randomized trial at the Sagol Center showing HBOT improved cognitive function, brain network connectivity, energy, sleep, psychiatric symptoms, cardiopulmonary function, and pain in Long COVID patients, with durable benefits up to one year post-treatment.

Kjellberg et al. (2023/2024) — A Swedish randomized, placebo-controlled, double-blind, Phase II trial examining 10 sessions of HBOT for Long COVID. While safety was confirmed, the short course (10 sessions) did not demonstrate benefit over placebo, suggesting minimum session numbers may be required for neurological effects.

A 2026 PMC systematic review concluded: "HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms and cardiopulmonary functions" and is safe for Long COVID, while calling for larger trials to define optimal protocols (PMC 2026, HBOT Long COVID).

TBI and PTSD in Veterans

Paul Harch MD (Louisiana State University) was among the first to document HBOT for traumatic brain injury, employing SPECT brain imaging to identify hypoperfused regions amenable to HBOT-induced neuroplasticity. His 2012 pilot trial in 16 military personnel with prolonged post-concussion syndrome and comorbid PTSD (15/16 patients) showed significant improvements in PTSD Checklist scores after 40 sessions at 1.5 ATA, from a mean PCL-M of 67.4 to 47.1 (Frontiers in Neuroscience, HBOT for Veterans PTSD).

Efrati and Doenyas-Barak's randomized, sham-controlled trial in Israeli combat veterans with chronic treatment-resistant PTSD used 60 sessions of HBOT and demonstrated significant decreases in CAPS-5 scores, with imaging confirming restored fronto-limbic connectivity and improved white matter integrity — structural changes correlating with symptom recovery. Many veterans who had been unable to work or maintain relationships returned to functioning after treatment (Psychiatric Times, 2025).

Fibromyalgia

Efrati's 2015 PLOS ONE prospective active-control crossover trial in 60 female FMS patients demonstrated that 40 sessions at 2 ATA produced significant amelioration of all fibromyalgia symptoms — pain, tender points, quality of life, sleep, and fatigue — with SPECT imaging showing normalized brain activity in pain-processing regions. Notably, 37.9% of HBOT-treated patients no longer met FMS diagnostic criteria post-treatment; no improvement was seen during the control period (PLOS ONE 2015).

Crohn's Disease and IBD

Multiple registry studies and the 2024 Chinese prospective trial have demonstrated HBOT's ability to modulate gut microbiome dysbiosis and reduce intestinal inflammation in Crohn's disease, with fecal microbiota transplantation experiments establishing causal relationships between HBOT-induced microbiome changes and anti-inflammatory outcomes (PMC 2024).

Part VII: Insurance, Cost Context, and the Off-Label Divide

Medicare-Approved Indications

The Centers for Medicare & Medicaid Services (CMS) approves HBOT for 14 specific indications, including:

1. Acute carbon monoxide intoxication

2. Decompression illness

3. Arterial gas embolism

4. Gas gangrene (clostridial myonecrosis)

5. Acute traumatic peripheral ischemia

6. Crush injuries and suturing of severed limbs

7. Progressive necrotizing infections

8. Acute peripheral arterial insufficiency

9. Compromised skin grafts and flaps

10. Chronic refractory osteomyelitis

11. Osteoradionecrosis and radiation tissue damage

12. Soft tissue radionecrosis

13. Diabetic wounds of the lower extremity — with strict criteria: Type 1 or 2 diabetes, Wagner Grade III or higher classification (wound penetrating to tendon, capsule, or bone), AND failure of an adequate course of standard wound therapy

14. Idiopathic sudden sensorineural hearing loss (in some jurisdictions)

(Medicare.gov, HBOT Coverage)

Cost Structure

A single HBOT session billed to Medicare was estimated at $595.86 in 2022 (UHMS, Trends in Medicare Costs). Full treatment courses for diabetic foot ulcers ranged from $17,875 to $35,751 (30–60 sessions). Private-pay rates for off-label indications typically run $250–$1,500 per session depending on facility type, geography, and chamber setting.

For Medicare-covered indications, patients typically pay 20% of the approved amount after the Part B deductible ($257 in 2025). For off-label indications — which include TBI, stroke, PTSD, long COVID, anti-aging, Alzheimer's, and fibromyalgia — virtually all costs are out-of-pocket. This creates a significant access and research barrier: the most scientifically interesting applications are self-pay, limiting participation in controlled trials and pushing clinical development to private centers.

Part VIII: Key Researchers and the Field's Architects

Paul Harch, MD (Louisiana State University Health Sciences Center, New Orleans) — America's foremost authority on HBOT and SPECT brain imaging in neurology. Pioneer in applying HBOT to TBI, chronic neurological conditions, and veterans with PTSD. Author of The Oxygen Revolution.

Shai Efrati, MD (Tel Aviv University; Director, Sagol Center for Hyperbaric Medicine and Research; Scientific Advisor, Aviv Clinics) — Israel's leading HBOT researcher. Has produced the most methodologically rigorous HBOT RCTs of the modern era, covering stroke, fibromyalgia, cognitive aging, PTSD, and Long COVID. Architect of the anti-aging HBOT protocol and the hyperoxic-hypoxic paradox framework.

Amir Hadanny, MD (Sagol Center; Aviv Clinics Chief Medical Research Officer) — Co-author of the landmark 2020 telomere study and multiple Sagol Center publications on HBOT mechanisms.

Stephen Thom, MD, PhD (University of Pennsylvania, Department of Emergency Medicine) — America's premier HBOT mechanisms researcher. His 2005–2006 work establishing CD34+ stem cell mobilization via nitric oxide-dependent pathways and his 2011 comprehensive mechanisms review are foundational literature in the field. Also contributed key work on neutrophil adherence inhibition and ischemia-reperfusion protection.

Robert Marx, DDS (University of Miami) — Maxillofacial surgeon who defined the pathophysiology of radiation tissue injury as "3-H tissue" and developed the Marx 20/10 and 30/10 protocols for osteoradionecrosis prevention and treatment. His randomized trials established HBOT as standard of care for head and neck cancer patients requiring dental procedures or surgery in irradiated fields.

Eric Kindwall, MD (deceased; Medical College of Wisconsin) — Often called the "father of modern American hyperbaric medicine." Editor of the field's definitive textbook (Hyperbaric Medicine Practice, 1994) and a founding force of the Undersea and Hyperbaric Medical Society (UHMS). Trained the first generation of American hyperbaric physicians.

George Hart, MD — Early UHMS leader who helped build the academic infrastructure of American hyperbaric medicine.

Ite Boerema, MD (University of Amsterdam) — Dutch cardiac surgeon whose 1960 "Life Without Blood" experiments provided the first rigorous demonstration of plasma-dissolved oxygen sufficiency, establishing the scientific basis for modern HBOT and earning him the title "father of modern hyperbaric medicine."

Conclusion

Hyperbaric oxygen therapy is among the most mechanistically complex interventions in medicine. Its effects cannot be reduced to "breathing more oxygen." The elevation of dissolved plasma oxygen is only the entry point: what follows is a cascade of ROS and RNS signaling, HIF-1α activation and paradoxical cycling, stem cell mobilization, angiogenesis, neuroplasticity, anti-inflammatory cytokine suppression, and — remarkably — apparent reversal of telomere shortening and cellular senescence.

The frontier research now converging on Long COVID, Alzheimer's, PTSD, and anti-aging represents a paradigm expansion from HBOT as a wound care adjunct to HBOT as a systemic regenerative and senolytic intervention. Whether this expansion will be supported by the rigorous randomized controlled trials the field requires — and whether insurance structures will evolve to reflect the emerging evidence — remains the central challenge of the next decade of hyperbaric medicine.

Sources cited include: StatPearls NCBI Hyperbaric Physics, UHMS HBO Indications 2020, Thom SR PMC 2011, Thom SR PubMed 2006 Stem Cells, PMC 2014 CD34+ Mobilization, PMC 2021 HBOT Anti-inflammatory, PMC 2020 Hyperoxic-Hypoxic Paradox, Hadanny/Efrati 2020 Telomeres PubMed, PMC full text telomere study, Efrati PLOS ONE 2013 Stroke, Efrati PLOS ONE 2015 Fibromyalgia, PMC 2019 HBOT Pulmonary, NCBI Contraindications, Medicare HBOT Coverage, UHMS Cost Analysis 2022, Frontiers Neuroscience PTSD Veterans, PMC 2026 Long COVID, PMC 2024 Gut Microbiota, PMC 2025 Gut Microbiota, Cleveland Historical Cunningham Sanitarium, Marx Protocols, NEDU Wikipedia, Duke Hyperbaric Center, Medscape HBOT, PMC HBOT Application 2025